Tibet Rhodiola Pharmaceutical Holding Company operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tibet Rhodiola Pharmaceutical Holding Company with three other
drug stores in Asia:
of South Korea
sales of 151.26 billion Korean Won [US$141.27 million]
Cosmo Bio Company Ltd
(7.07 billion Japanese Yen [US$66.65 million]
Hai-O Enterprise Berhad
based in Malaysia
(404.24 million Malaysian Ringgits [US$103.38 million]
of which 76%
was Multi-Level Marketing).
Tibet Rhodiola Pharmaceutical Holding Company reported sales of 915.63 million Chinese Renmimbi (US$144.53 million)
December of 2017.
increase of 14.9%
versus 2016, when the company's sales were 796.77 million Chinese Renmimbi.
Despite this increase, sales are still
below the level achieved in 2015, when Tibet Rhodiola Pharmaceutical Holding Company
reported sales of 1.38 billion Chinese Renmimbi.
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
211.9% in 2017, from
2.19 million Chinese Renmimbi to 6.83 million Chinese Renmimbi.
Not all segments of Tibet Rhodiola Pharmaceutical Holding Company experienced an increase in sales in 2017:
sales of Pharmaceutical Manufacturing Industry fell 60.3% to 315.35 million Chinese Renmimbi.